Merck said a study of its once-daily formulation of ISENTRESS (raltegravir) for the treatment of adults with HIV-1 infection found that after 48 weeks of treatment, 1200 mg raltegravir was statistically non-inferior to the marketed formulation approved dose of ISENTRESS 400 mg twice-daily. Furthermore, the study showed comparable rates of[Read More…]
Cintas shares rose to a new high on Wednesday after the provider of corporate identity uniforms and other items said late Tuesday that fiscal Q4 sales rose 11.3% to $1.27 billion from the year-ago level and were above the CapIQ mean for $1.25 billion. CTAS was up 12% at $108.79,[Read More…]
European equities opened higher on Monday underpinned by rallies in the mining and automobile sectors and reflecting a stock surge in Asia after incumbent Japanese Prime Minister Shinzo Abe and his ruling coalition secured a landslide victory in elections held on Sunday. The Japanese electoral win puts Abe in a[Read More…]
Equity Analyst Abhinav Davuluri of Investment Research Firm MorningStar issued a research report called ”2015 Headwins Expected to Persist in 2016 for Micron Technology, Inc.(NASDAQ:MU); Cutting Fair Value Estimate to $23 According to the report ”Micron reported fiscal fourth-quarter results that were in line with our expectations. PC-related DRAM once[Read More…]
Equity Analysts Karen Andersen, CFA and Stefan Quenneville, CFA of Investment Research Firm MorningStar issued a research report called ”Pricing Concerns in Pharma and Biotech Industries Creates Some Buying Opportunities and updated star rating on Exelixis, Inc.(NASDAQ:EXEL) According to the report ”Exelixis is best known for its R&D prowess for[Read More…]
